Insider Transaction Report for Arcellx, Inc.

This filing details a series of stock option transactions by Olivia C. Ware, a director at Arcellx, Inc. The transactions, which occurred on April 28, 2026, involved the cancellation and conversion of various stock options into cash payments and contingent value rights, as per the Agreement and Plan of Merger with Gilead Sciences, Inc. The options had exercise prices ranging from $7.61 to $63.68 per share, and were converted into rights to receive the difference between a closing amount of $115 per share and their respective exercise prices, plus one contingent value right per share. All post-transaction shares were zero, indicating the options were fully converted.